How Confident Should We Be in Psoriasis Biosimilars?

How Confident Should We Be in Psoriasis Biosimilars?

Join Drs Steven Feldman and Jonathan Kay as they examine the data on safety, switching, and confidence in psoriasis biosimilars. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep4-2026a10006hl [https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep4-2026a10006hl]. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.   Resources Psoriasis https://emedicine.medscape.com/article/1943419-overview [https://emedicine.medscape.com/article/1943419-overview] Lyme Disease https://emedicine.medscape.com/article/330178-overview [https://emedicine.medscape.com/article/330178-overview] Synovial Fluid Eosinophilia in Lyme Disease https://pubmed.ncbi.nlm.nih.gov/3056421/ [https://pubmed.ncbi.nlm.nih.gov/3056421/] Rheumatoid Arthritis (RA) Treatment & Management https://emedicine.medscape.com/article/331715-treatment [https://emedicine.medscape.com/article/331715-treatment] Psoriatic Arthritis Treatment & Management https://emedicine.medscape.com/article/2196539-treatment#d9 [https://emedicine.medscape.com/article/2196539-treatment#d9] A Review of Biosimilars for Rheumatoid Arthritis https://pubmed.ncbi.nlm.nih.gov/35552095/ [https://pubmed.ncbi.nlm.nih.gov/35552095/] Drift, Evolution, and Divergence in Biologics and Biosimilars https://pubmed.ncbi.nlm.nih.gov/24567263/ [https://pubmed.ncbi.nlm.nih.gov/24567263/] FDA Updates Guidance on Interchangeability https://www.fda.gov/drugs/drug-alerts-and-statements/fda-updates-guidance-interchangeability [https://www.fda.gov/drugs/drug-alerts-and-statements/fda-updates-guidance-interchangeability] Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention https://pubmed.ncbi.nlm.nih.gov/32205569/ [https://pubmed.ncbi.nlm.nih.gov/32205569/] Physicochemical and Biological Similarity Assessment of LBAL, a Biosimilar to Adalimumab Reference Product (Humira®) https://pubmed.ncbi.nlm.nih.gov/34262661/ [https://pubmed.ncbi.nlm.nih.gov/34262661/] GP2017, an Adalimumab Biosimilar: Pharmacokinetic Similarity to Its Reference Medicine and Pharmacokinetics Comparison of Different Administration Methods https://pubmed.ncbi.nlm.nih.gov/30698045/ [https://pubmed.ncbi.nlm.nih.gov/30698045/] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

How Much Monitoring Is Enough in Psoriasis Care?

Dr Steven Feldman joins Drs Jennifer Cather and Brad Glick to discuss how much monitoring systemic psoriasis treatments really require in modern practice. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep3-2026a10006hk [https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep3-2026a10006hk]. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Psoriasis https://emedicine.medscape.com/article/1943419-overview [https://emedicine.medscape.com/article/1943419-overview] Psoriasis: An Update on Topical and Systemic Therapies https://pubmed.ncbi.nlm.nih.gov/40568686/ [https://pubmed.ncbi.nlm.nih.gov/40568686/] Crosstalk Between White Adipose Tissue and Skin: Unraveling Its Role in Psoriasis Pathogenesis (Review) https://pubmed.ncbi.nlm.nih.gov/40242953/ [https://pubmed.ncbi.nlm.nih.gov/40242953/] Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis With Biologics https://pubmed.ncbi.nlm.nih.gov/30772098/ [https://pubmed.ncbi.nlm.nih.gov/30772098/] Joint American Academy of Dermatology-National Psoriasis Foundation Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologic Therapies https://pubmed.ncbi.nlm.nih.gov/32119894/ [https://pubmed.ncbi.nlm.nih.gov/32119894/] Oral Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/36751339/ [https://pubmed.ncbi.nlm.nih.gov/36751339/] Janus Kinase Inhibitors for Alopecia Areata: A Review of Clinical Data https://pubmed.ncbi.nlm.nih.gov/40433365/ [https://pubmed.ncbi.nlm.nih.gov/40433365/] Herpes Zoster https://emedicine.medscape.com/article/1132465-overview [https://emedicine.medscape.com/article/1132465-overview] Clinical Testing Guidance for Tuberculosis: Interferon Gamma Release Assay https://www.cdc.gov/tb/hcp/testing-diagnosis/interferon-gamma-release-assay.html [https://www.cdc.gov/tb/hcp/testing-diagnosis/interferon-gamma-release-assay.html] Utility of Repeat Latent Tuberculosis Testing With the QuantiFERON-TB Gold Test in Patients With Psoriasis Treated With Tumour Necrosis Factor-α Inhibitors at a Single U.S. Institution https://pubmed.ncbi.nlm.nih.gov/31452192/ [https://pubmed.ncbi.nlm.nih.gov/31452192/] Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents https://pubmed.ncbi.nlm.nih.gov/41191940/ [https://pubmed.ncbi.nlm.nih.gov/41191940/] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

Next-Gen Oral Therapies Reshaping Psoriasis Care

Drs Steven Feldman and Tina Bhutani-Jacques explore how next-generation oral therapies are closing the gap with biologics and reshaping psoriasis care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep2-2026a10006a5 [https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep2-2026a10006a5]. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Acitretin Revisited in the Era of Biologics https://pubmed.ncbi.nlm.nih.gov/20673152/ [https://pubmed.ncbi.nlm.nih.gov/20673152/] Apremilast in Psoriasis: Current Landscape and Perspectives https://pubmed.ncbi.nlm.nih.gov/40739686/ [https://pubmed.ncbi.nlm.nih.gov/40739686/] Deucravacitinib Versus Placebo and Apremilast in Moderate-to-Severe Plaque Psoriasis: Efficacy and Safety Results From the 52-Week, Randomized, Double-Blinded, Placebo-Controlled Phase 3 POETYK PSO-1 Trial https://pubmed.ncbi.nlm.nih.gov/35820547/ [https://pubmed.ncbi.nlm.nih.gov/35820547/] Apremilast Prescribing Information https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Otezla/otezla_pi_english.pdf Deucravacitinib Prescribing Information https://packageinserts.bms.com/pi/pi_sotyktu.pdf Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/39167366/ [https://pubmed.ncbi.nlm.nih.gov/39167366/] Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents https://pubmed.ncbi.nlm.nih.gov/38258121/ [https://pubmed.ncbi.nlm.nih.gov/38258121/] Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents https://pubmed.ncbi.nlm.nih.gov/41191940/ [https://pubmed.ncbi.nlm.nih.gov/41191940/] National Psoriasis Foundation https://www.psoriasis.org/ [https://www.psoriasis.org/] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

Can Fixing Adherence Fix Psoriasis Outcomes?

Join Drs Steven Feldman and Bernard Vrijens as they discuss the theory and practice of improving treatment adherence for better patient outcomes in psoriasis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep1-2026a10006a1 [https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep1-2026a10006a1]. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.   Resources Psoriasis https://emedicine.medscape.com/article/1943419-overview [https://emedicine.medscape.com/article/1943419-overview] The Importance of Assessing Drug Exposure and Medication Adherence in Evaluating Investigational Medications: Ensuring Validity and Reliability of Clinical Trial Results https://pubmed.ncbi.nlm.nih.gov/38135800/ [https://pubmed.ncbi.nlm.nih.gov/38135800/] Comparing Compliance Patterns Between Randomized Treatments https://pubmed.ncbi.nlm.nih.gov/9204220/ [https://pubmed.ncbi.nlm.nih.gov/9204220/] A Scoping Review of Studies Comparing the Medication Event Monitoring System (MEMS) With Alternative Methods for Measuring Medication Adherence https://pubmed.ncbi.nlm.nih.gov/27005306/ [https://pubmed.ncbi.nlm.nih.gov/27005306/] A New Taxonomy for Describing and Defining Adherence to Medications https://pubmed.ncbi.nlm.nih.gov/22486599/ [https://pubmed.ncbi.nlm.nih.gov/22486599/] One in 3 Prescriptions Are Never Redeemed: Primary Nonadherence in an Outpatient Clinic https://pubmed.ncbi.nlm.nih.gov/18467003/ [https://pubmed.ncbi.nlm.nih.gov/18467003/] Data Resource Profile: The Danish National Prescription Registry https://pubmed.ncbi.nlm.nih.gov/27789670/ [https://pubmed.ncbi.nlm.nih.gov/27789670/] Tachyphylaxis to Topical Glucocorticoids; What Is the Evidence? https://pubmed.ncbi.nlm.nih.gov/24010503/ [https://pubmed.ncbi.nlm.nih.gov/24010503/] Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents https://pubmed.ncbi.nlm.nih.gov/38258121/ [https://pubmed.ncbi.nlm.nih.gov/38258121/] 10 Tips to Improve Adherence to Immunosuppressive Medication After Kidney Transplantation https://pubmed.ncbi.nlm.nih.gov/40521289/ [https://pubmed.ncbi.nlm.nih.gov/40521289/] The Health Buddies App as a Novel Tool to Improve Adherence and Knowledge in Atrial Fibrillation Patients: A Pilot Study https://pubmed.ncbi.nlm.nih.gov/28724512/ [https://pubmed.ncbi.nlm.nih.gov/28724512/] 6MP Adherence in a Multiracial Cohort of Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/24829202/ [https://pubmed.ncbi.nlm.nih.gov/24829202/] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

Creams, Foams, and New Formulations: Rethinking Topical Therapy for Psoriasis

From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction. Join Drs Feldman and Armstrong as they discuss. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-psoriasis-s3-ep6-2026a100069z. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Psoriasis https://emedicine.medscape.com/article/1943419-overview [https://emedicine.medscape.com/article/1943419-overview] expertscape https://expertscape.com/ [https://expertscape.com/] PDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact https://pubmed.ncbi.nlm.nih.gov/40465498/ [https://pubmed.ncbi.nlm.nih.gov/40465498/] Topical Corticosteroids https://www.ncbi.nlm.nih.gov/books/NBK532940/ [https://www.ncbi.nlm.nih.gov/books/NBK532940/] Psoriasis Clinical Guideline https://www.aad.org/member/clinical-quality/guidelines/psoriasis [https://www.aad.org/member/clinical-quality/guidelines/psoriasis] Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The Correlation Between Disease Severity and Psychological Burden in Patients Treated With Biological Therapies https://pubmed.ncbi.nlm.nih.gov/23425140/ [https://pubmed.ncbi.nlm.nih.gov/23425140/] Keratosis Pilaris https://emedicine.medscape.com/article/1070651-overview [https://emedicine.medscape.com/article/1070651-overview] Review of the Mechanism of Action of Coal Tar in Psoriasis https://pubmed.ncbi.nlm.nih.gov/28814117/ [https://pubmed.ncbi.nlm.nih.gov/28814117/] Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence https://pubmed.ncbi.nlm.nih.gov/28188596/ [https://pubmed.ncbi.nlm.nih.gov/28188596/] Polyaphron Dispersion Technology, a Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application https://pubmed.ncbi.nlm.nih.gov/36050567/ [https://pubmed.ncbi.nlm.nih.gov/36050567/] Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits https://pubmed.ncbi.nlm.nih.gov/34106439/ [https://pubmed.ncbi.nlm.nih.gov/34106439/] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.